Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
- Authors
- Lee, Young-Sun; Jun, Hee-Sook
- Issue Date
- Jan-2014
- Publisher
- W B SAUNDERS CO-ELSEVIER INC
- Keywords
- Pancreatic islet; Incretin hormone; Type 2 diabetes; Proliferation; Anti-apoptosis
- Citation
- METABOLISM-CLINICAL AND EXPERIMENTAL, v.63, no.1, pp.9 - 19
- Journal Title
- METABOLISM-CLINICAL AND EXPERIMENTAL
- Volume
- 63
- Number
- 1
- Start Page
- 9
- End Page
- 19
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12952
- DOI
- 10.1016/j.metabol.2013.09.010
- ISSN
- 0026-0495
- Abstract
- Glucagon-like peptide-1 (GLP-1), an incretin hormone, is released from intestinal L-cells in response to nutrients. GLP-1 lowers blood glucose levels by stimulating insulin secretion from pancreatic beta-cells in a glucose-dependent manner. In addition, GLP-1 slows gastric emptying, suppresses appetite, reduces plasma glucagon, and stimulates glucose disposal, which are beneficial for glucose homeostasis. Therefore, incretin-based therapies such as GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase IV, an enzyme which inactivates GLP-1, have been developed for treatment of diabetes. This review outlines our knowledge of the actions of GLP-1 on insulin secretion and biosynthesis, beta-cell proliferation and regeneration, and protection against beta-cell damage, as well as the involvement of recently discovered signaling pathways of GLP-1 action, mainly focusing on pancreatic beta-cells. (C) 2014 Elsevier Inc. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 약학대학 > 약학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12952)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.